Research
Molecular
GLP-1 medicines may suppress tumorigenesis through various mechanisms.
Further research is needed to understand the mechanisms by which GLP-1 medicines may affect tumorigenesis.
StrongQualifiesmedium confidence
GLP-1 medicines acting through weight loss-dependent and weight loss-independent mechanisms hold potential for suppression of tumorigenesis.
Why this rating
The claim is based on data from preclinical cancer models.
Source
Glucagon-like peptide-1 medicines and cancer
Julian M. Yabut et al. · Nature Cancer · 2026
DOI 10.1038/s43018-025-01110-1
otherCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →